Prostatex Plus demonstrates superior efficacy over Prostatilen in treating chronic abacterial prostatitis category III B

Chronic prostatitis, particularly abacterial prostatitis category III B, remains a significant medical challenge with no optimal treatment regimens despite extensive research. Patients often experience persistent pain, urinary dysfunction, and reduced quality of life. Current therapeutic approaches frequently fall short in providing comprehensive relief. This study investigates the efficacy of Prostatex Plus, a prostate extract-containing medication, as a potential improved treatment option by comparing it against Prostatilen, another established prostate extract, to address the unmet need for more effective therapies.

An open-label, randomized cohort study enrolled 60 patients aged 37 to 57 years with chronic abacterial prostatitis, category III B. The main group (n=30) received Prostatex Plus 10 mg rectally once daily at night as part of combination therapy. The comparison group (n=30) received Prostatilen 3 mg rectally once daily at night as part of combination therapy. Both treatments were administered for 20 days. Efficacy and safety were assessed 14 days after treatment using NIH-CPSI, IPSS, and IIEF-5 questionnaires, clinical data, and laboratory and instrumental studies including urinalysis, prostate secretion analysis, uroflowmetry, and ultrasound data.

Patients receiving prostate extract-containing medications experienced a broad range of improvements. These included a reduction in prostate parameters and swelling, leading to normalization of urinalysis and prostate secretion parameters. Objective measures like uroflowmetry and ultrasound data showed stable improvements. Subjectively, patients reported a reduction in symptoms and complaints, which translated into improved urination quality, a reduction in pain, and alleviation of cardiac erectile dysfunction. Overall, these improvements contributed to an increased quality of life. While specific numerical data (e.g., percentages, p-values) were not provided in the abstract, a direct comparative analysis clearly demonstrated:

Prostatex Plus exhibited greater efficacy compared to Prostatilen across the assessed clinical and objective parameters.